We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Reference Material Aims to Improve Comparability of Angiotensin II Testing

By LabMedica International staff writers
Posted on 15 Sep 2026

Comparability of biomarker measurements across laboratories remains a persistent hurdle for clinical decision-making and method development. More...

Angiotensin II, a peptide hormone central to blood pressure and fluid-electrolyte regulation and used as a vascular disease biomarker, lacks easily accessible, consistent benchmarks. The limited supply of existing international reference materials further complicates traceability and validation. To address this gap, a new study describes the development and characterization of an additional reference material intended to strengthen comparability in angiotensin II testing.

Researchers developed and characterized a candidate reference material for angiotensin II (Ang II) to provide an additional measurement benchmark. The material is intended to serve as a common standard that laboratories can use to validate analytical methods, evaluate measurement performance, and compare results across platforms. The approach addresses practical barriers to method harmonization when current international materials are difficult to access or limited in supply.

Purity assignment relied on two independent metrological strategies—isotope dilution mass spectrometry (ID‑MS) and the mass balance method—that are based on different measurement principles. Despite their distinct principles, the two approaches yielded closely consistent results, increasing confidence in the assigned value. The material demonstrated excellent bottle-to-bottle homogeneity, and the relative expanded uncertainty of the assigned value was 1.8% (k=2).

For practical deployment, stability testing showed the material remained stable for at least 12 months at −20°C. Under simulated transportation conditions, it was stable for at least seven days at both 4°C and 25°C. Measurements were also verified against NRC ANG II-1, a certified reference material from the National Research Council Canada, and the comparison met the accepted equivalence criterion, supporting the accuracy of the assigned value.

According to the study, published in Biomedical Analysis, the new reference material can support method validation, laboratory quality control, performance evaluation, and traceable measurement of Ang II, helping make results more comparable across methods and laboratories. The authors note that characterization focused on metrological properties rather than biological activity. Its biological activity has not yet been examined, and further studies will be needed to determine whether it retains equivalent activity in vivo. Within this scope, the material provides an additional tool to strengthen standardization and traceability in Ang II testing.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: These images show breast tumors in a new preclinical model developed by Garvan researchers. The cells carry a fluorescent sensor that lights up blue/green when CDK1—the protein \'engine\' cells need to divide—is switched on. Using it, the team watched CDK1 activity rise as tumors became invasive and stay high in tumors that kept growing despite treatment. (Image Credit: Dr. Max Nobis / Garvan Institute)

Study Finds Potential Marker of Targeted Drug Resistance in Breast Cancer

Estrogen receptor-positive breast cancer is the most common breast cancer subtype and is driven by estrogen. Many patients are treated with CDK4/6 inhibitors alongside hormone therapy, but these drugs... Read more

Hematology

view channel
Image: Mayo Clinic researchers used genetic data from nearly 50,000 participants to identify sickle cell and beta-thalassemia carrier traits, highlighting how population-scale testing can complement existing screening (Image Credit: Adobe Stock)

Genetic Testing Offers Opportunities for Earlier Blood Disorder Carrier Identification

Inherited hemoglobin disorders can affect oxygen transport, yet individuals who carry only a trait may remain unaware of their status. People with sickle cell trait or beta-thalassemia trait often have... Read more

Microbiology

view channel
Image: The test uses serum or plasma from patients with suspected acute infection and symptoms lasting fewer than seven days and generates a score indicating the likelihood of bacterial infection. (Image Credit: Shutterstock)

Rapid Host-Response Assay Gains FDA Clearance to Help Distinguish Bacterial and Viral Infections

Bacterial and viral infections often cause similar symptoms, making early differentiation difficult in emergency and urgent care settings. Clinicians may need to begin treatment before traditional diagnostic... Read more

Pathology

view channel
AI: Artificial intelligence; CNN: Convolutional neural networks; ResNet: Residual neural network. (Xing-hua Gao from The First Hospital of China Medical University, China Image Source Link: https://www.ovid.com/jnls/cmj/fulltext/10.1097/cm9.0000000000004154~deep-learning-based-computational-pathology-technologies)

Review Highlights Progress and Validation Needs for AI in Digital Pathology

Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more

Industry

view channel
Image: The ExaccType ESR1 dPCR Kit uses digital PCR technology to detect key ESR1 mutations associated with acquired resistance to endocrine therapy. (Photo courtesy of  BIOTYPE)

Collaboration Expands Access to Tests for Cancer Treatment Resistance and Toxicity Risk

Precision medicine in oncology relies on molecular testing to identify biomarkers that can help guide treatment decisions. In hormone receptor-positive, HER2-negative metastatic breast cancer, ESR1 mutations... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.